Next Article in Journal
Combined Effects of Isokinetic Training and Botulinum Toxin Type A on Spastic Equinus Foot in Patients with Chronic Stroke: A Pilot, Single-blind, Randomized Controlled Trial
Next Article in Special Issue
Uremic Toxin Concentrations are Related to Residual Kidney Function in the Pediatric Hemodialysis Population
Previous Article in Journal
Monoclonal Antibody Combinations Prevent Serotype A and Serotype B Inhalational Botulism in a Guinea Pig Model
Previous Article in Special Issue
FGF23, Biomarker or Target?
Article Menu
Issue 4 (April) cover image

Export Article

Open AccessReview

Emerging Roles of Aryl Hydrocarbon Receptors in the Altered Clearance of Drugs during Chronic Kidney Disease

CAPES Foundation, Ministry of Education of Brazil, Brasília DF 70040-020, Brazil
Aix Marseille Université, INSERM, C2VN, 13005 Marseille, France
APHM, Conception Hospital, Centre de Néphrologie et Transplantation Rénale, 13005 Marseille, France
European Uraemic Toxin Working Group of ESAO, endorsed by ERA-EDTA [EUTox], 3500 Krems, Austria
Author to whom correspondence should be addressed.
Toxins 2019, 11(4), 209;
Received: 15 February 2019 / Revised: 12 March 2019 / Accepted: 3 April 2019 / Published: 7 April 2019
(This article belongs to the Special Issue Disposition of Uremic Toxins: The Challenges in Uremia)
PDF [696 KB, uploaded 7 April 2019]


Chronic kidney disease (CKD) is a major public health problem, since 300,000,000 people in the world display a glomerular filtration rate (GFR) below 60 mL/min/1.73m2. Patients with CKD have high rates of complications and comorbidities. Thus, they require the prescription of numerous medications, making the management of patients very complex. The prescription of numerous drugs associated with an altered renal- and non-renal clearance makes dose adjustment challenging in these patients, with frequent drug-related adverse events. However, the mechanisms involved in this abnormal drug clearance during CKD are not still well identified. We propose here that the transcription factor, aryl hydrocarbon receptor, which is the cellular receptor for indolic uremic toxins, could worsen the metabolism and the excretion of drugs in CKD patients. View Full-Text
Keywords: AhR; uremic toxins; drug clearance AhR; uremic toxins; drug clearance

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Santana Machado, T.; Cerini, C.; Burtey, S. Emerging Roles of Aryl Hydrocarbon Receptors in the Altered Clearance of Drugs during Chronic Kidney Disease. Toxins 2019, 11, 209.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Toxins EISSN 2072-6651 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top